Context Therapeutics Announces $100 Million Private Placement
Context Therapeutics Inc. (CNTX)
Company Research
Source: GlobeNewswire
Financing includes new and existing leading healthcare investors Proceeds, along with existing cash and cash equivalents, are expected to extend cash runway into 2028 PHILADELPHIA, May 02, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced that it has entered into a securities purchase agreement with certain new and existing investors in a private placement that is expected to result in gross proceeds of approximately $100.0 million, before deducting placement agent fees and estimated offering expenses. The private placement is expected to close on May 6, 2024, subject to the satisfaction of customary closing conditions. The private placement is led by new investor Nextech1, with participation from new and existing investors, including Ally Bridge Group, Avidity Partners, Blackstone Multi-Asset Investing, Blue Owl Healthcare Opportunities, Deep Track Capi
Show less
Read more
Impact Snapshot
Event Time:
CNTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CNTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CNTX alerts
High impacting Context Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
CNTX
News
- Context Therapeutics Inc. (NASDAQ: CNTX) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $4.50 price target on the stock.MarketBeat
- Context Therapeutics Inc. (NASDAQ: CNTX) is now covered by analysts at Piper Sandler Companies. They set an "overweight" rating and a $4.50 price target on the stock.MarketBeat
- Context Therapeutics Inc. (CNTX) Upgraded to Buy: Here's Why [Yahoo! Finance]Yahoo! Finance
- Context Therapeutics Inc. (NASDAQ: CNTX) had its price target raised by analysts at HC Wainwright from $4.00 to $5.00. They now have a "buy" rating on the stock.MarketBeat
- Context Therapeutics Inc. (NASDAQ: CNTX) had its price target raised by analysts at Maxim Group from $4.00 to $10.00. They now have a "buy" rating on the stock.MarketBeat
CNTX
Analyst Actions
- 5/9/24 - Maxim Group
CNTX
Sec Filings
- 5/16/24 - Form D
- 5/13/24 - Form SC
- 5/10/24 - Form SC
- CNTX's page on the SEC website